MedTrace Logo

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

NCT06293417 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3958

Last updated 2024-08-27

No results posted yet for this study

Summary

The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are:

* major adverse cardiovascular events within 48 months of the trial duration
* microvascular events within 48 months of the trial duration

Conditions

  • T2DM (Type 2 Diabetes Mellitus)
  • Dyslipidemias

Interventions

DRUG

Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin

Treatment group

DRUG

Dose escalation of moderate-intensity statin

Control group

Sponsors & Collaborators

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • SIN-GON KIM · Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2027-02-01
Completion
2027-02-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06293417 on ClinicalTrials.gov